About Catalyst Biosciences (NASDAQ:CBIO)
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors. The company is also developing CB 2679d/ISU304, a Factor IX drug, which has completed enrollment of a Phase I/II subcutaneous dosing trial for the prophylactic treatment of individuals with hemophilia B; and CB 2782, an anti-C3 protease program for the treatment of dry age-related macular degeneration (AMD), as well as CB 1965a, a Factor Xa therapeutic program used as a universal procoagulant. Catalyst Biosciences, Inc. has collaboration agreement with Pfizer, Inc. for the development of human Factor VIIa products; and ISU Abxis for development and manufacturing of the Factor IX products through Phase I/II clinical trials. The company has strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other retinal diseases. The company is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio-3.39
Forward P/E Ratio-8.31
Sales & Book Value
Annual Sales$1.02 million
Price / Sales295.57
Price / CashN/A
Book Value$5.29 per share
Price / Book4.77
EPS (Most Recent Fiscal Year)($7.45)
Return on Equity-39.27%
Return on Assets-34.64%
Catalyst Biosciences (NASDAQ:CBIO) Frequently Asked Questions
What is Catalyst Biosciences' stock symbol?
Catalyst Biosciences trades on the NASDAQ under the ticker symbol "CBIO."
When did Catalyst Biosciences' stock split? How did Catalyst Biosciences' stock split work?
Catalyst Biosciences shares reverse split on the morning of Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 10th 2017. An investor that had 100 shares of Catalyst Biosciences stock prior to the reverse split would have 7 shares after the split.
How were Catalyst Biosciences' earnings last quarter?
Catalyst Biosciences Inc (NASDAQ:CBIO) issued its quarterly earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, beating the Zacks' consensus estimate of ($1.15) by $0.59. The biopharmaceutical company earned $0.01 million during the quarter, compared to analyst estimates of $0.23 million. Catalyst Biosciences had a negative return on equity of 39.27% and a negative net margin of 2,983.40%. View Catalyst Biosciences' Earnings History.
When is Catalyst Biosciences' next earnings date?
What price target have analysts set for CBIO?
2 equities research analysts have issued 1-year price objectives for Catalyst Biosciences' stock. Their forecasts range from $44.00 to $75.00. On average, they expect Catalyst Biosciences' stock price to reach $59.50 in the next twelve months. View Analyst Ratings for Catalyst Biosciences.
Who are some of Catalyst Biosciences' key competitors?
Some companies that are related to Catalyst Biosciences include Alder Biopharmaceuticals (ALDR), Athenex (ATNX), Revance Therapeutics (RVNC), Retrophin (RTRX), Intra-Cellular Therapies (ITCI), Eagle Pharmaceuticals (EGRX), Esperion Therapeutics (ESPR), TG Therapeutics Inc common stock (TGTX), Epizyme (EPZM), Reata Pharmaceuticals (RETA), Dynavax Technologies (DVAX), Endocyte (ECYT), Flexion Therapeutics (FLXN), Vanda Pharmaceuticals (VNDA) and CytomX Therapeutics (CTMX).
Who are Catalyst Biosciences' key executives?
Catalyst Biosciences' management team includes the folowing people:
- Nassim Usman, Chief Exec. Officer, Pres and Director (Age 58)
- Mr. Fletcher Payne, Chief Financial Officer (Age 55)
- Dr. Howard Levy M.B.B.Ch., Ph.D., M.M.M., Chief Medical Officer (Age 64)
- Dr. Charles S. Craik, Co-Founder and Chairman of Scientific Advisory Board
- Dr. Jack Nguyen Ph.D., Co-Founder
Has Catalyst Biosciences been receiving favorable news coverage?
Headlines about CBIO stock have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Catalyst Biosciences earned a coverage optimism score of 0.20 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 45.05 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are Catalyst Biosciences' major shareholders?
Catalyst Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include Acuta Capital Partners LLC (9.67%), Sio Capital Management LLC (9.63%), venBio Select Advisor LLC (8.58%), Nexthera Capital LP (4.51%), BlackRock Inc. (1.56%) and Iguana Healthcare Management LLC (0.84%). View Institutional Ownership Trends for Catalyst Biosciences.
Which major investors are buying Catalyst Biosciences stock?
CBIO stock was acquired by a variety of institutional investors in the last quarter, including Sio Capital Management LLC, Acuta Capital Partners LLC, venBio Select Advisor LLC, Nexthera Capital LP, Iguana Healthcare Management LLC, Millennium Management LLC, EAM Global Investors LLC and Tibra Equities Europe Ltd. View Insider Buying and Selling for Catalyst Biosciences.
How do I buy shares of Catalyst Biosciences?
Shares of CBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Catalyst Biosciences' stock price today?
One share of CBIO stock can currently be purchased for approximately $25.25.
How big of a company is Catalyst Biosciences?
Catalyst Biosciences has a market capitalization of $301.36 million and generates $1.02 million in revenue each year. The biopharmaceutical company earns $-21,560,000.00 in net income (profit) each year or ($7.45) on an earnings per share basis. Catalyst Biosciences employs 13 workers across the globe.
How can I contact Catalyst Biosciences?
Catalyst Biosciences' mailing address is 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-266-8674 or via email at [email protected]
MarketBeat Community Rating for Catalyst Biosciences (CBIO)MarketBeat's community ratings are surveys of what our community members think about Catalyst Biosciences and other stocks. Vote "Outperform" if you believe CBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.